Roivant Sciences

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization

Leading innovation in medical dermatology Advancing potentially transformative therapies for autoimmune diseases Delivering results through nucleic acids Our CEO, Matt Gline, shares Roivant's progress and growth as VTAMA continues its positive impact on psoriasis patients, and Immunovant shares a new promising compound, IMVT-1402

Designing Better Molecules, Atom by Atom

We have built an end-to-end platform for heterobifunctional degrader discovery which we are expanding to other chemically-induced proximity applications Learn more

We’re expanding the druggable proteome and unlocking the next generation of high value small molecule therapeutics Learn more

Designing Best-in-Class Small Molecules

Our computation-first approach is used to design molecules that rapidly reach the desired TPP for disease areas where effective therapeutic solutions are lacking Learn more

Our discovery computational platform, QUAISAR (QUantum, AI, and Structure-Activity Relationships) is leveraged to gain critical project insights and desired properties for drug engineering

Rigorous Free Energy Simulations in Virtual Screening Virtual high throughput screening (vHTS) in drug discovery is a power approach to identify hits: when applied successfully, it can be much faster and cheaper than experimental high-throughput screening approaches However, mainstream vHTS tools have significant limitations: ligand-based methods depend on knowledge of existing chemical matter, while structure-based tools such as docking involve

Learn more about our work

Sign up for our latest announcements and upcoming presentations

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs